Overview

A Study in Pediatric Participants With Generalized Anxiety Disorder

Status:
Completed
Trial end date:
2013-06-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to find out if duloxetine [30-120 milligrams (mg)] given once a day by mouth for 10 weeks to children and adolescents, is better than placebo when treating Generalized Anxiety Disorder (GAD).
Phase:
Phase 3
Details
Lead Sponsor:
Eli Lilly and Company
Treatments:
Duloxetine Hydrochloride